Multi-Center Phase I Study of Th1/Tc1 Immunotherapy Following Autologous Hematopoietic Progenitor Cell Transplantation in Reccurrent or High Risk Plasma Cell Myeloma
Year: 2013
Type: article
Abstract: To date, despite recent progress in the treatment of Plasma Cell Myeloma (PCM), it remains an incurable disease in which prolonged therapy (maintenance) appears to be beneficial. Th1 immunity is critical in tumor immune surveillance and immune mediated tumor eradication, in particular of PCM. Immune reconstitution deficiency following autologous stem cell transplantation (AHCT) is believed to be a barrier to tumor eradication. Immunotherapy efforts and attempts to boost immunity with adoptive cell transfer have been thwarted by the short life span of the transferred cells.
Authors: Claude Sportes, Kristen Cole, David Siegel, Scott Rowley, David Halverson, Nancy Hardy, Steven Z. Pavletic, Juan Gea-Banacloche, Jennifer Mann, Amanda Urban, Vicki Fellowes, Marianna Sabatino, David F. Stroncek, Bruce Levine, Miriam Mossoba, Shoba Amarnath, Carl H. June, Ronald Gress, Daniel Fowler
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2053673272